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Abstract
B-cell depleting anti-CD20 monoclonal antibody therapies are being increasingly used as long-term maintenance therapy for 
neuroinflammatory disease compared to many non-neurological diseases where they are used as remission-inducing agents. 
While hypogammaglobulinaemia is known to occur in over half of patients treated with medium to long-term B-cell-depleting 
therapy (in our cohort IgG 38, IgM 56 and IgA 18%), the risk of infections it poses seems to be under-recognised. Here, we 
report five cases of serious infections associated with hypogammaglobulinaemia occurring in patients receiving rituximab for 
neuromyelitis optica spectrum disorders. Sixty-four per cent of the whole cohort of patients studied had hypogammaglobu-
linemia. We discuss the implications of these cases to the wider use of anti-CD20 therapy in neuroinflammatory disease.
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Introduction
B-cell-depleting anti-CD20 monoclonal antibody therapies 
have demonstrated significant clinical efficacy in individuals 
with neuroinflammatory disorders and are increasingly gain-
ing traction as a therapeutic approach. In particular, open 
label data consistently demonstrate favourable efficacy for 
rituximab (a chimeric anti-CD20 monoclonal antibody) 
on clinical outcomes in patients with neuromyelitis optica 
(NMO) [1] as well as a reduction in MRI and clinical meas-
ures of disease activity in phase-II studies of relapsing multi-
ple sclerosis (MS) [2–4]. More recently, ocrelizumab (a fully 
humanised anti-CD20 monoclonal) has also been shown to 
be effective in relapsing MS and is the first therapeutic agent 
to have exhibited a reduction in disability progression in 
a phase-III study of primary progressive MS [5, 6]. It has 
gained FDA approval and is expected to become a key drug 
for MS globally in the next few years.
Anti-CD20 monoclonal antibody therapy is typically used 
as maintenance therapy when it is prescribed for NMO or 
MS. This is in contrast to its widespread use in many non-
neurological diseases including rheumatoid arthritis and 
anti-neutrophil cytoplasmic antibody (ANCA)-associated 
vasculitis, in which anti-CD20 therapy is usually employed 
as a short-term remission-inducing agent before the sub-
sequent introduction of an alternative maintenance therapy 
[7]. While the use of maintenance anti-CD20 therapy has 
increased significantly in neurology, long-term safety data 
on its use in neuroinflammatory disease remain scarce.
A profound and durable depletion of circulating B cells 
occurs within days of rituximab infusion [8, 9]. The fact that 
plasma cells do not express CD20 and are, therefore, resist-
ant to the immediate depletory effects of anti-CD20 therapy 
is expected to preserve humoral immunity [10], but second-
ary antibody deficiency does occur [9, 11–14]. However, its 
frequency or consequences in neurological diseases have not 
been fully explored.
Here, we present a UK cohort of 50 individuals with 
NMO treated over extended periods with rituximab, five of 
whom developed serious infection in the context of second-
ary antibody deficiency. We consider the implications of 
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this case series and outline potential considerations in the 
long-term use of anti-CD20 monoclonal antibodies in NMO 
and other neuroinflammatory diseases.
Patient identification and acquisition of laboratory 
data
Management of individuals with NMO in England is coor-
dinated by the Walton Centre, Liverpool, and John Radcliffe 
Hospital, Oxford. Patients in Wales are referred to regional 
specialist services, including Cardiff. Disease-specific data-
bases and detailed longitudinal clinical data are available in 
all centres. Interrogation of the Liverpool and Cardiff data-
sets was used to identify any individual with a diagnosis 
of NMO or NMO spectrum disorder (NMO-SD) who had 
been treated with rituximab since 2007 (Liverpool n = 50, 
Cardiff n = 6). Results of laboratory investigations includ-
ing serum immunoglobulins were known for 50 out of 56 
patients. Review of case records was undertaken in a sub-
set of patients known to have experienced severe infection 
(defined as requiring hospital admission and IV antibiotics) 
in the context of hypogammaglobulinaemia (reduced blood 
concentration of IgG, IgM and/or IgA).
All patients provided consent for their data to be used as 
part of ethically approved research studies (reference num-
bers 15/L0/1433 and 05/WSE03/111). Immunoglobulin lev-
els (IgG, IgA and IgM) were assayed by nephelometry (Sie-
mens BN2 Nephelometer; Siemens) and specific antibody 
titres against Haemophilus influenzae (Hib), Clostridium 
tetani (tetanus) and Pneumococcal capsular polysaccharide 
were determined by ELISA (The Binding Site, Birming-
ham, UK). Protective cut-off levels of circulating specific 
antibodies were tetanus > 0.1 IU/ml, Haemophilus influ-
enzae > 1mcg/ml and Pneumococcal antibodies > 50 mg/L 
[15].
A total of 33 archived serum samples were available, 
from disease-specific biobanks, from the five cases with 
severe infection. Samples were analysed for immunoglobulin 
levels over 14.6 patient-years (mean 2.7 samples per patient 
per year). A total of 19 samples were analysed for disease-
specific Igs over 15.3 patient-years (mean 1.3 samples per 
patient per year).
Results
Serum immunoglobulins
Immunoglobulin levels were available for 50 patients at 
some time point. Baseline (pre-rituximab) values were 
available for 23 cases. Four of the 23 cases in whom sera 
were available (8% of the cohort) were recorded to have low 
baseline IgG (< 6.0 g/L) and a further 15 out of 50 (30%) 
patients were recorded as developing IgG deficiency at 
some stage during rituximab therapy. Overall, 28 patients 
(56%) were detected to have IgM deficiency (< 0.4 g/L) at 
some stage during rituximab therapy (one of whom had 
low levels at baseline) and 9 (18%) were found to have IgA 
deficiency (< 0.8 g/L) during rituximab therapy (one of 
whom had low levels at baseline). The mean nadir of IgG 
was 4.5 g/L recorded after a mean of 3.4 years of rituxi-
mab therapy (median 3.5, range 0.2–8.9). Overall 18 out of 
50 (36%) patients receiving rituximab were not recorded to 
have immunoglobulin deficiency (mean follow-up duration 
3.2 years).
Cases of severe infection
Five out of 50 cases were identified had experienced severe 
infection in the context of low serum Ig. All were female and 
all had aquaporin-4 antibody-positive NMO. Clinical and 
demographic features are shown in Table 1. Serial immu-
noglobulin data are shown in Fig. 1. 
Case 1
Presented in 1987, aged 9 years with intractable vomit-
ing and left optic neuritis. Her MRI brain showed multiple 
areas of T2 hyperintensity consistent with CNS demyelinat-
ing disease and she had unpaired CSF oligoclonal bands. 
She initially received a diagnosis of MS and had 1 year of 
beta-interferon therapy. She went on to experience three 
further episodes of optic neuritis and at least five episodes 
of myelitis, each followed by poor recovery despite intra-
venous steroids. By 2006, when the anti-AQP4 antibody 
had become widely available and she tested positive; at 
that time she was registered blind with an EDSS of 6. She 
had 6-monthly plasma exchange for 18 months following 
6 months of azathioprine. Side-effects and evidence of ongo-
ing CNS inflammatory activity prompted consideration of 
rituximab. Baseline (pre-rituximab) EDSS was 7.5. Base-
line immunoglobulins were normal; however, IgG was in 
the lower half of the normal range and anti-pneumococcal 
and anti-HiB antibodies were both low (tested in retro-
spect using biobanked serum) (Fig. 1). In retrospect, using 
archived serum samples, low IgG was first detectable after 
3.6 years of rituximab. After 6.2 years of rituximab, she 
presented with chronic cough and was found to have bilat-
eral bronchiectasis on CT chest imaging in the absence of 
a smoking history. She was concurrently being investigated 
for hearing loss and was found to have bilateral suppurative 
otitis media with perforation of both tympanic membranes. 
At the time, serum IgG was 4.4 g/L (normal range 6–16), 
IgA 0.5 g/L (normal range 0.8–3) and IgM 0.2 (normal range 
0.4–2.5). Shortly after the diagnosis of bronchiectasis, she 
developed superimposed Mycoplasma pneumoniae infection 
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necessitating several weeks in an intensive care unit (ICU). 
She recovered from her pneumonia although she remains 
severely hearing impaired. She elected to continue with 
6-monthly rituximab infusions but now receives additional 
3-weekly immunoglobulin replacement therapy (IGRT), 
which has significantly decreased her infection burden. Her 
EDSS has remained stable (7.5) during 9 years of rituximab 
therapy.
Case 2
Presented in 2006, aged 45y with bilateral, sequential optic 
neuritis followed by poor visual recovery. She had a pre-
vious history of arm and leg weakness compatible with 
myelitis some years earlier. Investigations ultimately ful-
filled diagnostic criteria for AQP4 + NMO in 2009. She 
was commenced on azathioprine but experienced break-
through disease activity and deranged liver function dur-
ing 3 months of mycophenolate therapy. By the time she 
commenced rituximab therapy in 2011, EDSS had reached 
7. She had low baseline IgM and low anti-HiB antibodies 
(tested in retrospect using biobanked serum). In retrospect, 
using archived serum samples, low IgG was first detectable 
after 2.3 years of rituximab. After 4.5 years of rituximab 
therapy, she developed chronic cough, in the absence of a 
smoking history, which persisted despite several courses 
of antibiotics. Sputum culture revealed a heavy growth of 
Haemophilus influenzae. Chest X-rays were normal but she 
was found to have bilateral bronchiectasis on high-resolution 
CT chest imaging. She had monitoring of immunoglobu-
lin levels, received antibiotic prophylaxis and a course of 
back-up antibiotics for breakthrough respiratory infective 
symptoms. She was vaccinated against pneumococcus and 
HiB but subsequent disease-specific antibody measurements 
showed that she did not mount a protective response. She 
elected to continue with 6-monthly rituximab therapy, hav-
ing experienced 4 years of relapse freedom. Despite preven-
tative measures, she developed an episode of septicaemia 
due to urinary tract infection in 2017. IgG at the time was 
5.1 g/L, IgM < 0.17 g/L and IgA normal. She was in hospital 
for 11 days, requiring fluid resuscitation, IV antibiotics and 
IGRT. Since recovering from her most recent infection, she 
has elected to continue with rituximab therapy with addi-
tional regular IGRT. Her current EDSS is 7.5.
Case 3
Presented in 2015, aged 53y with longitudinally extensive 
transverse myelitis and was found to meet diagnostic criteria 
for AQP4 + NMO. She was treated briefly with mycophe-
nolate in 2015 but switched to azathioprine due to gastric 
ulceration. She commenced rituximab in 2016, when her 
EDSS was 6. Her baseline IgG was in the lower half of the Ta
bl
e 
1 
 (c
on
tin
ue
d)
Ag
e a
t 
di
se
as
e o
ns
et 
(y
ea
rs)
Cu
m
ul
ati
ve
 
du
ra
tio
n a
nd
 
ty
pe
 of
 D
M
T 
pr
io
r t
o R
TX
 
(in
 or
de
r 
gi
ve
n)
Du
ra
tio
n o
f 
di
se
as
e a
t 
RT
X 
on
se
t 
(y
ea
r)
ED
SS
 
at 
RT
X 
on
se
t
Ba
se
lin
e 
Ig
G 
(g
/L
)*
RT
X 
tre
atm
en
t 
sc
he
du
le
AR
R 
pr
e-
 
RT
X
AR
R 
po
st-
RT
X
Ti
m
e f
ro
m
 
RT
X 
to
 
de
tec
tio
n 
of
 lo
w 
Ig
G 
(y
ea
rs)
RT
X 
du
ra
-
tio
n a
nd
 
cu
m
ul
ati
ve
 
do
se
 at
 ti
m
e 
of
 se
ve
re
 
in
fec
tio
n
Ig
s a
t t
im
e 
of
 se
ve
re
 
in
fec
tio
n 
(lo
w 
tit
re
s i
n 
bo
ld
)*
Na
tu
re
 of
 
se
ve
re
 in
fec
-
tio
n
On
go
in
g m
an
-
ag
em
en
t
Ca
se
 5
15
2.0
 ye
ar
s; 
Az
a, 
M
M
F
3
4.0
10
.1
(p
re
-R
TX
)
2 g
 ev
er
y 
6 m
on
th
s 
fo
r 3
y t
he
n 
CD
19
-le
d.
Co
nc
ur
re
nt
 
pr
ed
ni
-
so
lo
ne
 
fo
r fi
rst
 
3 y
ea
rs 
of
 
RT
X.
2.2
0
3.5
3.5
y, 
14
 g
Ig
G 
3.1
Ig
M
 0.
2
Ig
A 
0.9
Hi
B 
1.6
Pn
eu
m
 30
Te
t 0
.7
Pn
eu
m
on
ia
Sw
itc
he
d t
o 
CD
19
-le
d 
in
fu
sio
ns
 
an
d I
gG
 
no
rm
ali
se
d. 
Di
sc
on
tin
-
ue
d p
ro
ph
y-
lac
tic
 ab
x 
th
er
ea
fte
r.
Ab
x 
an
tib
io
tic
s, 
AR
R  
an
nu
ali
se
d 
re
lap
se
 ra
te,
 A
za
 a
za
th
io
pr
in
e, 
ED
SS
 E
xp
an
de
d 
di
sa
bi
lit
y 
sta
tu
s s
ca
le,
 H
iB
 a
nt
i-h
ae
m
op
hi
lu
s 
in
flu
en
za
 a
nt
ib
od
ie
s, 
Ig
s i
m
m
un
og
lo
bu
lin
s, 
m
ito
x 
m
ito
xa
nt
ro
ne
, 
M
M
F 
m
yc
op
he
no
lat
e m
of
eti
l, 
PL
Ex
 pl
as
m
a e
xc
ha
ng
e, 
pn
eu
m
o a
nt
i-p
ne
um
oc
oc
ca
l a
nt
ib
od
ies
, R
TX
 ri
tu
xi
m
ab
, T
et
 an
ti-
tet
an
us
 an
tib
od
ies
, I
G
RT
 - I
m
m
un
og
lo
bu
lin
 R
ep
lac
em
en
t T
he
ra
py
*N
or
m
al 
ra
ng
es
: I
gG
 6–
16
 g/
L,
 Ig
M
 0.
4–
2.5
 g/
L,
 Ig
A 
0.8
–3
 g/
L,
 H
iB
 >
 1m
cg
/m
l, 
Pn
eu
m
 >
 50
 m
g/
L,
 T
et 
> 
0.1
 IU
/m
l
Journal of Neurology 
1 3
normal range. Baseline disease-specific antibodies are una-
vailable. She was treated with 6-monthly rituximab infusions 
with concurrent prednisolone for the first 12 months. Low 
serum IgG (tested in retrospect using biobanked serum) was 
first detectable after 4.5 months of rituximab. She devel-
oped Legionella pneumonia after 11 months of rituximab 
treatment, necessitating invasive ventilation on ICU. She 
recovered from her pneumonia and elected to continue with 
6-monthly rituximab therapy. Her hypogammaglobulinae-
mia has persisted and despite vaccination against pneumo-
coccus and HiB, she has continued to experience recurrent 
chest infections requiring frequent courses of antibiotics and 
is planned for IGRT.
Case 4
Presented with a brainstem syndrome in 1997, aged 39y 
and experienced subsequent recurrent optic neuritis and 
myelitis. She was diagnosed clinically with NMO in 2004 
and confirmed to have AQP4 antibodies in 2008. She had 
chronic obstructive airways disease and continued to smoke 
cigarettes. She received a single pulse of mitoxantrone in 
2004 and then commenced azathioprine and prednisolone. 
She was switched briefly to mycophenolate in 2014 but 
commenced rituximab in 2015 because of side-effects and 
breakthrough disease activity on previous agents. At the time 
her EDSS was 7.5. Baseline IgG levels and anti-pneumococ-
cal antibodies were both low. She continued prednisolone 
(daily dose 10–15 mg) alongside her rituximab therapy. She 
developed pneumonia in 2015; at the time her serum IgG 
was 4.7 g/L (normal IgM and IgA). In early 2016, she com-
menced antibiotic prophylaxis and rituximab infusions were 
scheduled according to B-cell repopulation. Despite these 
measures, she continued to experience recurrent pneumonia 
over a 12-month period and ultimately died from her infec-
tion in late 2016.
Case 5
Developed optic neuritis in 2009, aged 15y. She experi-
enced further episodes of optic neuritis and myelitis, and 
was found to fulfil diagnostic criteria for NMO in 2010. She 
Fig. 1  Serial immunoglobulins measured in the five individuals with 
hypogammaglobulinemia and severe infection. In each case, serial 
measurements are plotted on the y-axis, against time from the com-
mencement of rituximab (baseline) on the x-axis. Dashed black lines 
indicate the lower levels of the normal ranges. Data were censored at 
time of immunoglobulin replacement therapy where relevant. a IgG, 
b IgM, c IgA, d Anti-pneumococcal antigen antibodies. e Anti-teta-
nus antibodies, f Anti-HiB antibodies
 Journal of Neurology
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was commenced on azathioprine and switched to mycophe-
nolate in 2011 and then to rituximab in 2012 because of 
breakthrough disease activity. At the time of commenc-
ing rituximab her EDSS was 4.0 and serum Igs (including 
disease-specific antibodies) were normal. She continued to 
receive daily prednisolone for the first 3 years of rituximab 
therapy. In 2015 she developed sinusitis and chest infec-
tions, which were initially managed in the community. At 
that time her serum IgG was 3.1 g/L and IgM was also 
low (0.2 g/L; IgA normal). Later that year she developed 
pneumonia and required hospitalisation for IV antibiotics. 
She recovered from her severe infection and elected to con-
tinue with rituximab therapy. Her rituximab schedule was 
switched from 6-monthly infusions to retreatment according 
to B-cell repopulation. Serum IgG level normalised and she 
has not experienced any further infections.
Discussion
B-cell-depleting anti-CD20 monoclonal antibody therapies 
demonstrate favourable clinical efficacy for individuals with 
CNS inflammatory disease but long-term safety data are 
scarce. Hypogammaglobinaemia was recorded in 64% of 
patients (32 out of 50) for whom data were available in this 
UK cohort. Severe infection associated with secondary anti-
body deficiency occurred in 5 out of 50 (10% of the entire 
cohort). This value may underestimate the true prevalence, 
as infection and immunoglobulin data were not systemati-
cally surveyed in all patients.
This case series illustrates several additional insights. 
First, rituximab had sustained clinical efficacy in patients 
that had not been achieved with prior disease-modifying 
therapies (mean pre-treatment annualised relapse rate of 1.8 
versus 0.4 post-rituximab). This was a key factor influencing 
the decision to continue using rituximab in all cases, despite 
the episodes of infection. Second, laboratory and clinical 
surveillance is required to detect the earliest signs of these 
treatment-associated infections. Third, a combination of 
serum immunoglobulin measurement plus disease-specific 
antibody titres appears optimal to determine risk, maxim-
ise the opportunity for preventative measures and avoid the 
development of bronchiectasis.
A profound and durable depletion of circulating B cells 
occurs within days of rituximab infusion [8, 9]. As plasma 
cells do not express CD20, they are unaffected and have hith-
erto provided some assurance that humoral immunity would 
be sufficiently preserved [10]. However, it remains unclear 
whether long-term humoral immunity results entirely from 
a self-sustaining long-lived plasma cell (LLPC) popula-
tion that survive for decades, or whether regular replenish-
ment of plasma cells by memory B cells is required every 
few months [16]. Despite the apparent survival of LLPCs 
after B-cell depletion [17–19], several clinical studies have 
observed a dose-dependent reduction in serum immunoglob-
ulins following anti-CD20 therapy [11, 12, 14, 20]. This 
implies that long-term humoral immunity may be more reli-
ant on replenishment of plasma cells from the B-cell pro-
genitor pool than previously thought.
The finding that B-cell depletion lasts an average of 
6 months [21], led to regular 6-monthly dosing of rituxi-
mab during many early regimens. However, the consider-
able inter-individual variation in repopulation time has led 
several authors to recommend retreatment guided by B-cell 
repopulation, mainly to avoid risk of neurological relapse in 
those who repopulate early. The use of CD19 + (a pan B-cell 
marker) monitoring in NMO was initially suggested but the 
incidence of NMO relapses occurring even at low levels 
of CD19 + B-cell repopulation suggests this approach may 
compromise disease control [9, 11]. The observation that the 
return of CD27 + (memory B cells) coincides with the return 
of disease activity in rheumatoid arthritis prompted use of 
CD27 + B-cell monitoring to guide retreatment of NMO [11, 
22]. Retreatment guided by CD27 + repopulation has been 
reported to lower the cumulative dose of rituximab while 
maintaining remission in the majority of patients (91 out of 
100 cases) but is not universally available in clinical labo-
ratories [11, 23].
These data may have implications for use of similar 
B-cell depleting drugs, notably the newly approved ocre-
lizumab for MS. Despite considerable inter-individual 
variation observed in time-to-repopulation of B cells fol-
lowing ocrelizumab [24], dosing is recommended to occur 
at regular 6-monthly intervals [25]. No data were reported 
on immunoglobulin levels in phase-III ocrelizumab stud-
ies in MS but there was no excess of serious infection 
in ocrelizumab-treated patients during the 96 weeks of 
follow-up [6, 25]. It is possible that the risk of secondary 
antibody deficiency may be higher in an NMO popula-
tion where other immunosuppressive agents often precede 
anti-CD20 therapy. The subnormal IgG and pneumococ-
cal antibodies observed pre-rituximab in case 4 (who had 
already received mitoxantrone, azathioprine and mycophe-
nolate over 10 years) highlight the possible contribution of 
prior immunotherapy to secondary antibody deficiency. A 
review of risk factors predisposing to the development of 
hypogammaglobulinaemia and infections post-rituximab 
identified low immunoglobulins prior to treatment, main-
tenance therapy with rituximab, prior immunosuppression, 
concomitant purine analogues such as mycophenolate and 
chronic lung or heart disease as well as older age [26]. In 
four out of five of our cases, the combined duration of pre-
vious immunosuppressive therapy and rituximab treatment 
exceeded 5 years, suggesting that secondary antibody defi-
ciency may be a dose- and duration-dependent phenom-
enon. Therefore, it is possible that other CD-20-depleting 
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drugs including ocrelizumab may with long-term treat-
ment have similar effects. However, case 3 had received 
only 4  months of immunosuppression and 11  months 
of rituximab therapy before developing severe infection 
associated with secondary antibody deficiency. Possible 
explanations for the early development of severe infection 
in this case include the co-administration of maintenance 
corticosteroid.
The occurrence of recurrent or complicated infections 
of the upper and/or lower respiratory tract in our case 
series is typical of antibody deficiency and illustrates the 
need for surveillance that extends beyond blood monitor-
ing [27]. Monitoring of patients on anti-CD20 therapy 
should include regular questioning on infective burden 
with a particular focus on sino-pulmonary symptoms.
In retrospect, using archived sera, we were able to dem-
onstrate downward trends in serum immunoglobulin levels 
that occurred after the commencement of rituximab. Due 
to low awareness of this complication of B-cell-depleting 
therapies, serum immunoglobulin surveillance was not 
routinely undertaken in this series until recently, leading 
to delays in detection and treatment in some cases. How-
ever, the hypogammaglobulinaemia that coincided with 
severe infection was often modest and the presence of 
subnormal baseline protective levels of disease-specific 
antibodies to HiB and/or pneumococcus suggests that they 
may add additional functional information to help stratify 
for the risk of infection during anti-CD20 therapy. Test 
vaccination as used in the assessment of humoral immu-
nodeficiency may also play a role.
Screening of patients before rituximab therapy for 
serum immunoglobulins and disease-specific antibodies 
opens up the possibility for therapeutic vaccination, which 
is more challenging once B cells are depleted. Detection of 
on-therapy secondary antibody deficiency ought to prompt 
close infection surveillance and consideration of back-up 
or prophylactic antibiotics and/or IGRT to prevent infec-
tion and end organ damage. If further pooled long-term 
data confirm secondary antibody deficiency as a prevalent 
complication, management algorithms allied to those used 
for primary antibody deficiency may be required [27].
In summary, this case series highlights a serious com-
plication of anti-CD20 depletion therapy when used as 
remission maintenance treatment for neuroinflammatory 
disease. While NMOSD is a relatively rare disease, this 
observation is potentially generalisable to other diseases 
treated with B-cell depletion. It is particularly important 
in the ocrelizumab era of MS treatment. Progressive MS 
patients who may benefit from ocrelizumab may have addi-
tional comorbidities that predispose them to infections. 
Heightened awareness of this potentially preventable and 
treatable complication is crucial to avoid added morbidity 
and mortality and to allow patients to continue benefiting 
from a highly effective mode of therapy.
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